The stock price of Cabaletta Bio Inc (NASDAQ: CABA) has surged by 20.77 when compared to previous closing price of 1.30, but the company has seen a 29.75% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-15 that – Two subtype specific cohorts with ~15 patients each added to the ongoing RESET-Myositis™ trial – – RMAT designation granted for rese-cel in myositis, which is a disabling, multi-system autoimmune disease affecting approximately 80,000 U.S. patients with no approved treatments other than monthly IVIg – – Multiple Phase 1/2 disease cohorts fully enrolled across the RESET™ clinical development program; 44 patients enrolled and 23 patients dosed as of May 9, 2025 – – SLE and LN registrational discussions with FDA anticipated in 3Q25; systemic sclerosis registrational discussions with FDA anticipated in 4Q25 – – New clinical data on rese-cel in myositis, SLE / LN and systemic sclerosis to be presented in three oral sessions at the EULAR 2025 Congress in June – PHILADELPHIA, May 15, 2025 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced plans for an anticipated 2027 rese-cel BLA submission following a recent U.S. Food and Drug Administration (FDA) meeting on a proposed registrational cohort design for the RESET-Myositis trial of rese-cel (resecabtagene autoleucel, formerly known as CABA-201). “Myositis is a severe, disabling, and potentially life-threatening multi-system disease that affects approximately 80,000 patients in the U.S. with a three-fold increased mortality risk primarily due to interstitial lung disease, cardiovascular disease and an increased risk of cancer.
Is It Worth Investing in Cabaletta Bio Inc (NASDAQ: CABA) Right Now?
The stock has a 36-month beta value of 2.65. Opinions on the stock are mixed, with 8 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for CABA is 45.71M, and at present, short sellers hold a 13.34% of that float. On May 15, 2025, the average trading volume of CABA was 933.48K shares.
CABA’s Market Performance
CABA stock saw an increase of 29.75% in the past week, with a monthly gain of 40.18% and a quarterly increase of -41.85%. The volatility ratio for the week is 8.38%, and the volatility levels for the last 30 days are 8.60% for Cabaletta Bio Inc (CABA). The simple moving average for the last 20 days is 23.62% for CABA stock, with a simple moving average of -48.76% for the last 200 days.
Analysts’ Opinion of CABA
Many brokerage firms have already submitted their reports for CABA stocks, with Evercore ISI repeating the rating for CABA by listing it as a “In-line.” The predicted price for CABA in the upcoming period, according to Evercore ISI is $6 based on the research report published on December 20, 2024 of the previous year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see CABA reach a price target of $6, previously predicting the price at $12. The rating they have provided for CABA stocks is “Equal Weight” according to the report published on December 19th, 2024.
UBS gave a rating of “Buy” to CABA, setting the target price at $10 in the report published on October 10th of the previous year.
CABA Trading at 11.93% from the 50-Day Moving Average
After a stumble in the market that brought CABA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.37% of loss for the given period.
Volatility was left at 8.60%, however, over the last 30 days, the volatility rate increased by 8.38%, as shares surge +40.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.84% lower at present.
During the last 5 trading sessions, CABA rose by +25.62%, which changed the moving average for the period of 200-days by -78.53% in comparison to the 20-day moving average, which settled at $1.2675. In addition, Cabaletta Bio Inc saw -30.84% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CABA
The total capital return value is set at -0.79. Equity return is now at value -59.64, with -52.35 for asset returns.
Based on Cabaletta Bio Inc (CABA), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -5.66. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -167.3.
Currently, EBITDA for the company is -125.14 million with net debt to EBITDA at 1.31. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.15.
Conclusion
To sum up, Cabaletta Bio Inc (CABA) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
